Agreement for accessing data of NGS based ctDNA tests

Xue Wu
xue.wu@geneseeq.com

Request Access

Dataset ID	Description	Technology	Samples
EGAD00001003176	For each subject, genomic DNA from whole blood, circulating cell free DNA and tumor tissues (whenever possible) were performed targeting next generation sequencing on Illumina Miseq or Hiseq 4000 platforms. The sequencing results of whole blood were used to distinguish germline and somatic mutations. Specimens were collected from patients with different kinds of solid tumors, but most are lung cancer patients.	Illumina HiSeq 4000 Illumina MiSeq	1845
EGAD00001004164	Whole exome and RNA-seq of matched normal gastric mucosa (n=34) and gastric cancer tissues (n=34) from gastric cancer patients (n=34)	Illumina HiSeq 4000	136
EGAD00001005798	The sequencing results provided in this study is enriched through liquid phase hybridization capture. The data set shows 35 clinical cfDNA samples showing a dominant peak at 166bp and 35 clinical cfDNA samples showing a dominant peak at 134/144bp.	HiSeq X Ten Illumina HiSeq 4000 Illumina MiSeq	70
EGAD00001006213	WES data of paired primary and metastatic tumors	HiSeq X Ten Illumina HiSeq 4000	179
EGAD00001006287	NGS data of 12 patients enrolled in the Chinese Patient Assistance Program from multiple centers who received pemetrexed alone or combined with platinum as initial chemotherapy and continued pemetrexed maintenance therapy for advanced lung adenocarcinoma from November 2014 to June 2017.	HiSeq X Ten Illumina HiSeq 4000	12